What SISCAPA Assay Technologies does

SISCAPA Assay Technologies, Inc. is a Washington, DC-based private proteomics company founded in 2011 that develops and commercializes the SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) immuno-affinity mass spectrometry platform for quantitative measurement of protein biomarkers and therapeutic proteins. The technology combines high-affinity anti-peptide antibody enrichment of proteolytically derived surrogate peptides with stable isotope-labeled internal standards and targeted mass spectrometry detection, enabling interference-free quantification across a >10^10-fold dynamic range, sub-ng/mL sensitivity in complex matrices, and multiplexing of up to ~50 assays in a single run. The company has built a catalog of more than 350 validated assays against diverse protein biomarkers, including FDA-cleared clinical markers such as thyroglobulin, where its clinical test has produced over 150,000 patient results through reference laboratories worldwide.

SISCAPA monetizes primarily through professional services: custom assay development (peptide selection, antibody reagent development, automated workflow optimization, and transfer to client CROs) and CRO-style analytical services including non-GLP sample analysis and multiplex panel execution. It also sells catalog assays outright and operates the LongitudeDX sub-brand, which combines dried blood spot sampling, wearable sensor integration, and the SampleDiary module for high-frequency longitudinal biomarker monitoring. Customers are pharmaceutical and biotechnology companies, gene therapy developers, diagnostic firms, academic researchers, and clinical reference laboratories. A wholly-owned Canadian subsidiary supports North American operations, and a June 2026 strategic collaboration with Biognosys extends assay accessibility into regulated clinical trial environments through Biognosys' CRO infrastructure.

The company is founder-controlled (N. Leigh Anderson, CEO and inventor of SISCAPA; Terry Pearson, CSO; Constance Seniff, VP Business Operations), with board oversight from seasoned diagnostics operators including a former Olink Proteomics chair and a biotech entrepreneur-investor. Capitalization has been modest: three disclosed funding rounds totaling roughly $3.56M between 2012 and 2025. The company competes on scientific depth and assay breadth rather than scale, with no publicly disclosed revenue and no AI/ML layer on top of its chemistry platform.

Name

SISCAPA Assay Technologies

Legal name

SISCAPA Assay Technologies, Inc.

Website

https://siscapa.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

SISCAPA Assay Technologies develops and commercializes the SISCAPA immuno-affinity mass spectrometry platform for quantitative protein biomarker and therapeutic protein measurement, serving pharmaceutical, biotech, diagnostic, and clinical reference laboratory customers via custom assay development, CRO analytical services, and a 350+ assay catalog.

Ownership category

akta.pro rank

Product category

Targeted Protein Assays & Clinical Proteomics Services

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industries

Proteomics & Mass Spectrometry Services (HLAGANAB), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)

Keywords

• Immunoaffinity mass spectrometry
• Targeted protein assays
• Biomarker quantification services
• Clinical proteomics assays
• Therapeutic antibody measurement

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Custom assay development services: Development of bespoke SISCAPA assays for client-identified proteins including peptide selection, immuno-affinity reagent development, automated assay optimization and qualification, and implementation in various matrices.
2. CRO analytical services: Non-GLP sample analysis and multiplex panel analysis combining novel and catalog assays for pharmaceutical and biotech clients.
3. Catalog assay menu: Over 350 SISCAPA assays developed against diverse protein biomarkers available for purchase, covering clinically-established protein targets including many FDA-cleared clinical markers.
4. Longitudinal dried blood spot studies: DBS study support including mobile health components and wearable sensor integration for biomarker monitoring.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

SISCAPA Assay Technologies develops and delivers immunoaffinity-mass spectrometry assays (the SISCAPA platform) that combine specific anti-peptide antibody enrichment with targeted mass spectrometry detection to quantify protein biomarkers and therapeutic proteins. The company sells a catalog of 350+ SISCAPA assays, performs custom assay development, and runs CRO analytical services for pharmaceutical, biotech, and diagnostic clients, with extensions into longitudinal dried blood spot monitoring via its LongitudeDX sub-brand.

Product overview

SISCAPA Assay Technologies offers a platform-based portfolio centered on immuno-affinity-mass spectrometry (IA-MS) assays for protein quantification. The core product is the SISCAPA Immuno-Affinity-MS workflow, which combines anti-peptide antibody enrichment with mass spectrometry detection to provide highly sensitive, specific, and multiplexed protein measurements. This core platform is extended through specialized assay panels (Inflammation, Oncology, Iron Metabolism), the LongitudeDX longitudinal monitoring sub-brand with its SampleDiary sampling system, and custom assay development and CRO analytical services. A strategic partnership with Biognosys extends the platform's accessibility into regulated clinical trial environments.

Differentiator

Problem solved

Functional benefit

Brands

• LongitudeDX: Proprietary platform for longitudinal measurement of protein biomarkers using dried blood spots (DBS), enabling researchers to accurately monitor endogenous and synthetic proteins in blood over time for disease dynamics and treatment efficacy insights.
• SampleDiary

Products and services

• SISCAPA Immuno-Affinity-MS Assays Targeted protein quantification assays combining specific anti-peptide antibody enrichment with mass spectrometry detection, offering high sensitivity, specificity, and multiplexing capabilities for measuring protein drugs, targets, and biomarkers in various biological matrices for pharmaceutical, biotech, and diagnostic customers.
• SISCAPA Assay Development Services Custom assay development services including peptide selection, immuno-affinity reagent development and supply, automated assay optimization and qualification, and implementation in serum, dried blood spot, tissue, and other matrices with transfer to regulated CROs.
• CRO Analytical Services Contract research organization analytical services providing non-GLP sample analysis, multiplex panels combining novel and catalog assays, and longitudinal dried blood spot studies for pharmaceutical and biotech clients.
• LongitudeDX A longitudinal health monitoring platform utilizing dried blood spot sampling combined with SISCAPA assay panels for high-frequency, personalized tracking of protein biomarkers over time, integrated with mobile health components and wearable sensor data.
• SampleDiary A compact, user-friendly dried blood spot sampling system augmented with automated contextual information gathering from wearable sensors, enabling high-frequency biomarker tracking for personalized health monitoring.
• Inflammation Panel A multiplexed panel of inflammation markers including CRP, SAA, orosomucoid, LPS-binding protein, mannose-binding lectin, haptoglobin, complement C3, fibrinogen, IgM, and myeloperoxidase for tracking inflammatory responses across clinically relevant timescales.
• Oncology Panel A panel of cancer-related protein biomarkers including FDA-cleared markers (AFP, CEA, PSA, mesothelin) and drug target proteins (PD-1, BTK) for oncology research and clinical monitoring.
• Iron Metabolism Panel An integrated panel measuring iron metabolism components including transferrin, soluble transferrin receptor, hemopexin, ferritin, hepcidin, ferroportin, hemoglobin, and haptoglobin for studying conditions like anemia, thalassemia, and neurodegeneration with brain iron accumulation.

Quantifiable outcome

• Over 350 SISCAPA assays developed against diverse protein biomarkers
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• BiognosyscoreStrategic or Co-development Partner · 12 June 2026SISCAPA formed a collaboration with Biognosys to develop ultra-sensitive targeted protein assays for clinical research. The partnership combines SISCAPA's immuno-enrichment technology with Biognosys' proteomics expertise and infrastructure. Biognosys provides state-of-the-art infrastructure and regulatory rigor to make SISCAPA assays broadly accessible in regulated environments, enabling deployment across the full drug development pipeline from preclinical studies to clinical trials.
• BrukerminorStrategic or Co-development PartnerPartnership with Bruker expanded hybrid metabolomics offerings. This collaboration complements SISCAPA's targeted proteomics capabilities by enabling combined multiomics solutions for discovery, translational, and clinical research.
• BiocratesminorStrategic or Co-development PartnerPartnership with Biocrates expanded hybrid metabolomics offerings alongside Bruker. This collaboration enables combined multiomics solutions for biomarker discovery and clinical research applications.
• LongitudeDXcoreTechnology or IntegrationLongitudeDX is a SISCAPA product platform (separate website at longitudedx.com) that revolutionizes longitudinal measurement of protein biomarkers using dried blood spots. The platform integrates proprietary techniques with mobile health components and wearable sensors for comprehensive biomarker tracking over time.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Olink Proteomics: Provides targeted protein biomarker discovery and measurement using proximity extension assay (PEA) technology coupled with NGS readout. A direct competitor to SISCAPA in high-multiplex targeted proteomics for pharma/biotech R&D; now owned by Thermo Fisher, giving it substantially greater scale.
• Quanterix: Developer of the Simoa single-molecule array platform for ultra-sensitive protein detection in blood and biofluids. Competes with SISCAPA in high-sensitivity protein biomarker measurement for neurology, oncology, and infectious disease applications.
• SomaLogic (Standard BioTools): Operates the SomaScan aptamer-based proteomics platform measuring thousands of proteins simultaneously. A direct peer in targeted protein biomarker profiling for pharma R&D, clinical trials, and translational research, now part of Standard BioTools.
• Meso Scale Diagnostics: Offers MULTI-ARRAY electrochemiluminescence immunoassays for multiplexed protein biomarker quantification. Competes with SISCAPA in pharma/biotech biomarker and PK/PD assays where high sensitivity and multiplexing are required.
• BioAgilytix: Bioanalytical CRO specializing in large-molecule PK/PD, immunogenicity, and biomarker assays for biologics, biosimilars, and gene/cell therapies. A direct peer to SISCAPA's CRO analytical services targeting pharma and biotech customers.
• Celerion: Contract research organization providing bioanalytical services, including LC-MS/MS-based protein quantification and biomarker assays. Direct peer to SISCAPA's CRO analytical services for pharma/biotech drug development programs.

Broad incumbents

• Bio-Techne: Diversified life science tools company with ProteinSimple branded analytical instruments, reagents, and the Simple Western platform. A broad incumbent serving proteomics and protein analysis customers, with substantially greater resources than SISCAPA.
• Eurofins Bioanalytical Services: Global bioanalytical laboratory network offering LC-MS/MS, immunoassay, and biomarker services for pharma and biotech. A broad incumbent providing similar CRO services to SISCAPA but at significantly larger scale.
• Promega: Developer of reagents, assays, and integrated systems for protein analysis, cell biology, and molecular diagnostics. A broad incumbent serving pharma/biotech researchers with bioanalytical tools that overlap with SISCAPA's workflow reagents.

Others

• Abcam: Global supplier of high-quality protein research tools, including antibodies and immunoassay reagents. Related ecosystem participant whose reagents and kits are often used alongside SISCAPA-style immuno-affinity workflows in protein research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/siscapa
• YouTubeyoutube.com/channel/UCmDQJYr_EzynJ-10VNoU9bA
• LinkedInlinkedin.com/company/siscapa-assay-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SISCAPA Assay Technologies